NGR018: Randomized Phase II Study of NGR-hTNF Plus Pegylated Liposomal Doxorubicin (PLD) Versus PLD in Platinum-resistant Ovarian Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2017
At a glance
- Drugs NGR-TNF (Primary) ; Doxorubicin; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors MolMed
- 26 Jan 2017 This trial has been completed in Italy.
- 01 Apr 2015 Planned End Date changed from 1 Feb 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 01 Apr 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History